HistoRx, Inc.
17Patents
17Active
17Granted
50Portfolio score
Filing activity: May 7, 2007 → Feb 5, 2013 · 9 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7709222B2 | Methods for making cancer prognoses based on subcellular localization of biomarkers | Physics | 15 | Active |
| US7978258B2 | Automatic exposure time selection for imaging tissue | Electricity | 14 | Active |
| US8160348B2 | Methods and system for validating sample images for quantitative immunoassays | Physics | 10 | Active |
| US7907271B2 | Method and system for standardizing microscope instruments | Physics | 9 | Active |
| US8121365B2 | Method and system for determining an optimal dilution of a reagent | Physics | 7 | Active |
| US8335360B2 | Compartment segregation by pixel characterization using image data clustering | Physics | 5 | Active |
| US8427635B2 | Method and system for standardizing microscope instruments | Physics | 4 | Active |
| US8878983B2 | Automatic exposure time selection for imaging tissue | Electricity | 4 | Active |
| US8314931B2 | Method and system for standardizing microscope instruments | Physics | 3 | Active |
| US8417015B2 | Methods and system for validating sample images for quantitative immunoassays | Physics | 2 | Active |
| US8120768B2 | Method and system for standardizing microscope instruments | Physics | 2 | Active |
| US8027030B2 | Method and system for standardizing microscope instruments | Physics | 2 | Active |
| US8367351B2 | Methods for determining signal transduction activity in tumors | Emerging Cross-Sectional Technologies | 1 | Active |
| US8497080B2 | Methods for determining signal transduction activity in tumors | Emerging Cross-Sectional Technologies | 1 | Active |
| US8655037B2 | Compartment segregation by pixel characterization using image data clustering | Physics | 0 | Active |
| US8605971B2 | Method and system for determining an optimal dilution of a reagent | Physics | 0 | Active |
| US8557527B2 | Correlation of molecular markers with clinical outcome in GBM patients radiation treated with or without gefitinib | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.